Published in Mol Cell on November 01, 2003
Visualization of molecular interactions by fluorescence complementation. Nat Rev Mol Cell Biol (2006) 3.79
Bimolecular fluorescence complementation (BiFC) analysis as a probe of protein interactions in living cells. Annu Rev Biophys (2008) 3.48
Design and implementation of bimolecular fluorescence complementation (BiFC) assays for the visualization of protein interactions in living cells. Nat Protoc (2006) 3.22
Characterization of cytoplasmic caspase-2 activation by induced proximity. Mol Cell (2009) 2.18
NF-kappaB and AP-1 connection: mechanism of NF-kappaB-dependent regulation of AP-1 activity. Mol Cell Biol (2004) 1.96
Bimolecular fluorescence complementation: visualization of molecular interactions in living cells. Methods Cell Biol (2008) 1.41
Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors. Oncogene (2005) 1.29
Therapeutic effect of topical administration of SN50, an inhibitor of nuclear factor-kappaB, in treatment of corneal alkali burns in mice. Am J Pathol (2005) 1.21
Inhibitory kappa B Kinases as targets for pharmacological regulation. Br J Pharmacol (2012) 1.14
Thymosin beta 4 suppression of corneal NFkappaB: a potential anti-inflammatory pathway. Exp Eye Res (2007) 1.04
Spatiotemporal patterns and transcription kinetics of induced RNA in single bacterial cells. Proc Natl Acad Sci U S A (2009) 1.03
Entamoeba histolytica cysteine proteinase 5 binds integrin on colonic cells and stimulates NFkappaB-mediated pro-inflammatory responses. J Biol Chem (2010) 1.02
Characterization of NF-kappa B/I kappa B proteins in zebra fish and their involvement in notochord development. Mol Cell Biol (2004) 1.01
Defective feedback regulation of NF-kappaB underlies Sjogren's syndrome in mice with mutated kappaB enhancers of the IkappaBalpha promoter. Proc Natl Acad Sci U S A (2010) 1.00
Toll-like receptor 4 signaling in dysfunction of cardiac microvascular endothelial cells under hypoxia/reoxygenation. Inflamm Res (2010) 0.98
Central pathways causing fatigue in neuro-inflammatory and autoimmune illnesses. BMC Med (2015) 0.97
MEKK3 is required for lysophosphatidic acid-induced NF-kappaB activation. Cell Signal (2009) 0.96
Restoration of NF-kappaB activation by tumor necrosis factor alpha receptor complex-targeted MEKK3 in receptor-interacting protein-deficient cells. Mol Cell Biol (2004) 0.96
Inhibition of NF-kappaB activity by IkappaBbeta in association with kappaB-Ras. Mol Cell Biol (2004) 0.96
Analyses of in vivo interaction and mobility of two spliceosomal proteins using FRAP and BiFC. PLoS One (2008) 0.95
Homeostatic interactions between MEKK3 and TAK1 involved in NF-kappaB signaling. Cell Signal (2008) 0.95
The Rsr1/Bud1 GTPase interacts with itself and the Cdc42 GTPase during bud-site selection and polarity establishment in budding yeast. Mol Biol Cell (2010) 0.95
The MC159 protein from the molluscum contagiosum poxvirus inhibits NF-κB activation by interacting with the IκB kinase complex. J Immunol (2012) 0.94
Loss of Arp2/3 induces an NF-κB-dependent, nonautonomous effect on chemotactic signaling. J Cell Biol (2013) 0.93
TRAF2 phosphorylation promotes NF-κB-dependent gene expression and inhibits oxidative stress-induced cell death. Mol Biol Cell (2010) 0.91
The role of caspase-2 in stress-induced apoptosis. J Cell Mol Med (2010) 0.91
New insights into the biogenesis of nuclear RNA polymerases? Biochem Cell Biol (2010) 0.89
Molecular basis of lysophosphatidic acid-induced NF-κB activation. Cell Signal (2010) 0.89
MEKK2 kinase association with 14-3-3 protein regulates activation of c-Jun N-terminal kinase. J Biol Chem (2013) 0.87
Genome-wide bimolecular fluorescence complementation analysis of SUMO interactome in yeast. Genome Res (2013) 0.86
Potential role of CYLD (Cylindromatosis) as a deubiquitinating enzyme in vascular cells. Am J Pathol (2008) 0.85
TCR Signaling in T Cell Memory. Front Immunol (2015) 0.84
Natural compound methyl protodioscin protects against intestinal inflammation through modulation of intestinal immune responses. Pharmacol Res Perspect (2015) 0.84
Phosphorylation of Thr-516 and Ser-520 in the kinase activation loop of MEKK3 is required for lysophosphatidic acid-mediated optimal IkappaB kinase beta (IKKbeta)/nuclear factor-kappaB (NF-kappaB) activation. J Biol Chem (2010) 0.80
Duration of alpha 1-antichymotrypsin gene activation by interleukin-1 is determined by efficiency of inhibitor of nuclear factor kappa B alpha resynthesis in primary human astrocytes. J Neurochem (2005) 0.79
TNF-α Modulation of Intestinal Tight Junction Permeability Is Mediated by NIK/IKK-α Axis Activation of the Canonical NF-κB Pathway. Am J Pathol (2016) 0.78
Anthrax lethal toxin enhances IkappaB kinase activation and differentially regulates pro-inflammatory genes in human endothelium. J Biol Chem (2009) 0.78
Impact of lysophosphatidylcholine on the plasminogen activator system in cultured vascular smooth muscle cells. J Korean Med Sci (2012) 0.75
ER arrival sites for COPI vesicles localize to hotspots of membrane trafficking. EMBO J (2016) 0.75
Cytokine-induced autophagy promotes long-term VCAM-1 but not ICAM-1 expression by degrading late-phase IκBα. Sci Rep (2017) 0.75
One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol (2008) 15.05
Regulation of the germinal center response by microRNA-155. Science (2007) 12.25
Pancreatic cancer. Lancet (2004) 11.63
Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid (2009) 10.20
Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell (2006) 10.10
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol (2006) 6.77
Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res (2008) 5.21
Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Radiology (2005) 4.96
Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology (2009) 4.72
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol (2010) 4.69
Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol (2006) 4.50
Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol (2008) 4.34
Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res (2008) 4.29
Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res (2009) 4.19
Metastatic patterns in adenocarcinoma. Cancer (2006) 4.16
Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg (2007) 4.09
Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA (2009) 3.86
Canonical NF-kappaB activity, dispensable for B cell development, replaces BAFF-receptor signals and promotes B cell proliferation upon activation. Immunity (2006) 3.74
Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology (2002) 3.59
Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res (2009) 3.57
Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res (2007) 3.53
Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol (2008) 3.45
Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol (2004) 3.43
Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell (2007) 3.37
Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc (2009) 3.36
Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg (2008) 3.36
Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol (2009) 3.22
TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. Nature (2002) 3.21
Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol (2004) 3.10
Yin Yang 1 is a critical regulator of B-cell development. Genes Dev (2007) 3.06
LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther (2008) 2.99
Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene (2003) 2.79
Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol (2008) 2.78
Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin Cancer Res (2005) 2.76
Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg (2004) 2.62
Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol (2006) 2.61
KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell (2012) 2.55
HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene (2005) 2.53
Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol (2008) 2.53
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol (2009) 2.52
TNF family member B cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology. J Immunol (2004) 2.51
ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS One (2011) 2.49
Inhibition of transcription factor NF-kappaB in the central nervous system ameliorates autoimmune encephalomyelitis in mice. Nat Immunol (2006) 2.48
Population-based study of islet cell carcinoma. Ann Surg Oncol (2007) 2.44
Use of research biopsies in clinical trials: are risks and benefits adequately discussed? J Clin Oncol (2012) 2.43
Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer (2007) 2.40
Risk factors for pancreatic cancer: case-control study. Am J Gastroenterol (2007) 2.40
The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene (2004) 2.35
Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res (2003) 2.27
Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. Ann Diagn Pathol (2011) 2.23
A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res (2003) 2.23
Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res (2005) 2.22
B cells lacking the tumor suppressor TNFAIP3/A20 display impaired differentiation and hyperactivation and cause inflammation and autoimmunity in aged mice. Blood (2010) 2.17
Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res (2012) 2.17
Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res (2005) 2.16
Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res (2006) 2.15
Enterocyte-specific A20 deficiency sensitizes to tumor necrosis factor-induced toxicity and experimental colitis. J Exp Med (2010) 2.15
Phosphatidylcholine synthesis for lipid droplet expansion is mediated by localized activation of CTP:phosphocholine cytidylyltransferase. Cell Metab (2011) 2.14
Intraductal papillary mucinous neoplasms of the pancreas: effect of invasion and pancreatic margin status on recurrence and survival. Ann Surg Oncol (2006) 2.12
Function of nuclear factor kappaB in pancreatic cancer metastasis. Clin Cancer Res (2003) 2.11
Improved preoperative planning for directed parathyroidectomy with 4-dimensional computed tomography. Surgery (2006) 2.09
14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition. Cancer Cell (2009) 2.09
Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol (2006) 2.07
Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer (2010) 2.04
The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States. J Hepatol (2008) 2.02
Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer (2004) 2.02
Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog (2008) 2.01
Mesocaval shunting: a novel technique to facilitate venous resection and reconstruction and enhance exposure of the superior mesenteric and celiac arteries during pancreaticoduodenectomy. J Am Coll Surg (2013) 1.98
NF-kappaB and AP-1 connection: mechanism of NF-kappaB-dependent regulation of AP-1 activity. Mol Cell Biol (2004) 1.96
Diagnostic strategies for unknown primary cancer. Cancer (2004) 1.93
IkappaB kinase signaling is essential for maintenance of mature B cells. J Exp Med (2002) 1.93
Association between hepatitis B virus and pancreatic cancer. J Clin Oncol (2008) 1.93
Combined EUS with FNA and ERCP for the evaluation of patients with obstructive jaundice from presumed pancreatic malignancy. Gastrointest Endosc (2008) 1.92
RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid (2005) 1.89
Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol (2013) 1.89